ArticleVaccines2024
Tracking Measles and Rubella Elimination Progress-World Health Organization African Region, 2022-2023.
Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).Vaccines · 2026Article
- Seroprevalence of measles-specific IgG and genotype-specific neutralizing antibody responses in clinically confirmed cases during the 2021-2023 measles outbreaks in Liberia.Research square · 2026Article
- Individual and population level uncertainty interact to determine the performance of outbreak surveillance systems.PLoS computational biology · 2026Article
- Article
- Article
- Progress towards measles and rubella elimination in Eswatini by 2024.PLOS global public health · 2026Article
- A large measles outbreak in Zimbabwe related to vaccine hesitancy in 2022.The Pan African medical journal · 2026Article
- Serological survey to determine measles and rubella immunity gaps across age and geographic locations in The Gambia: a study protocol.Global health action · 2025Article
- Epidemiology: Temporal and spatial patterns of measles in Amhara Region, Ethiopia, 2019-2024: implications for targeted intervention.BMC infectious diseases · 2025Article
- New approaches to measles eradication, with special reference to Africa.The Pan African medical journal · 2025Article
- The African measles and rubella laboratory network: 21 years of functioning in West Africa.The Pan African medical journal · 2025Article
- Time to first dose of measles-containing vaccine and associated factors among infants in Ethiopia: a survival analysis from performance monitoring for action data.Frontiers in public health · 2025Article
- Progress of Measles and Rubella Surveillance in the Context of Measles Elimination in the WHO Eastern Mediterranean Region, 2019-2022.Vaccines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Measles or rubella elimination is verified when endemic transmission of the corresponding virus has been absent for over 36 months in a defined area, in the presence of a well-performing surveillance system. This report updates the progress by 47 countries in the WHO African Region towards the goal of attaining verification of measles and rubella elimination in at least 80% of the countries of the region by 2030. We reviewed the WHO-UNICEF vaccination coverage estimates for the first and second doses of measles- and measles-rubella-containing vaccines, as well as the available coverage data for measles supplementary immunization activities, during 2022-2023. We also reviewed the measles-surveillance performance and analyzed the epidemiological trends of measles and rubella as reported in the case-based surveillance database. The WHO-UNICEF estimates of first measles vaccine dose (MCV1) and second measles vaccine dose (MCV2) coverage for the African Region for 2022 were 69% and 45%, respectively. Rubella-containing vaccines have been introduced in the routine immunization program in 32 of 47 (68%) countries as of the end of 2022, with no introductions during 2023. In 2022 and 2023, a total of 144,767,764 children were vaccinated in the region with measles or MR vaccines in 24 countries through 32 mass vaccination campaigns. The administrative coverage target of 95% was reached in only 15 (49%) of the 32 vaccination campaigns. In 2023, a total of 125,957 suspected cases of measles were reported through the case-based surveillance system, and 73,625 cases (58%) were confirmed to be measles, either by laboratory testing, by epidemiological linkage, or based on clinical compatibility. A total of 4805 confirmed rubella cases were reported, though this total represents substantial under-ascertainment. The regional incidence of measles was 60.3 cases per million population. Twenty-six countries (55%) met the targets for the two principal surveillance system performance-monitoring indicators. No country in the region has attained the verification of measles or rubella elimination as of the end of 2023. Addressing systemic problems with routine immunization and using tailored approaches to reach unvaccinated children can contribute to progress towards measles and rubella elimination. In addition, periodic and timely high-quality preventive SIAs remain a critical programmatic strategy to reach unvaccinated children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.